Clinical Trials Browser

Phase 2/3 × peginterferon alfa-2b × Clear all

NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Phase 2/3 Completed

Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Phase 2/3 Terminated

126 enrolled 9 charts

Melanoma